Lapatinib (ditosylate monohydrate)

Lapatinib ditosylate monohydrate (GW572016 ditosylate monohydrate) is a potent inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively[1].

Product Specifications

CAS Number

[388082-78-8]

Product Name Alternative

GW572016 (ditosylate monohydrate) ; GW2016 (ditosylate monohydrate)

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Autophagy; EGFR; Ferroptosis

Type

Reference compound

Related Pathways

Apoptosis; Autophagy; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/lapatinib-ditosylate-monohydrate.html

Concentration

10mM

Purity

99.99

Solubility

DMSO : 50 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

O=S(CCNCC1=CC=C(C2=CC3=C(NC4=CC=C(OCC5=CC=CC(F)=C5)C(Cl)=C4)N=CN=C3C=C2)O1)(C)=O.O=S(C6=CC=C(C)C=C6)(O)=O.O=S(C7=CC=C(C)C=C7)(O)=O.O

Molecular Formula

C43H44ClFN4O11S3

Molecular Weight

943.48

Precautions

H302, H315, H319, H335

References & Citations

[1]Rusnak DW, et al. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo. Mol Cancer Ther. 2001 Dec;1 (2) :85-94.